Horizon Therapeutics Plc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 16.16
Dividend & YieldN/A$ (N/A)
Beta 1.08
Market capitalization 17.85B
Operating cash flow 1.37B
ESG Scores unknown

Company description

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Sector: Healthcare - Industry: Drug Manufacturers—General

Financial Ratios
Quick Ratio2.72
Working Capital0.28
Return On Equity0.11
Debt To Equity0.55
Fixed Asset Ratio0.49
Fixed Interest Cover7.58

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -4.99M -8.72M 16.02M -12.2M
Total Cashflows From Investing Activities 27.65M -17.86M -464.07M -2.99B
Net Borrowings -27.72M -625.17M -1.74M 1.56B
Total Cash From Financing Activities -16.6M -290.45M 904.58M 1.47B
Change To Operating Activities -38.99M -46.67M -89.07M -85.61M
Issuance Of Stock 25.58M 362.99M 972.82M 73.09M
Net Income -38.38M 573.02M 389.8M 534.49M
Change In Cash 204.22M 117.92M 1B -499.32M
Effect Of Exchange Rate -1.38M -107k 7.24M -10.61M
Total Cash From Operating Activities 194.54M 426.33M 555.69M 1.04B
Depreciation 6.12M 6.73M 24.3M 17.47M
Change To Account Receivables -59.7M 56.17M -251.17M 34.8M
Other Cashflows From Financing Activities 3.3M 3.3M
Change To Netincome 53.81M -403.95M 219.48M 203.58M
Capital Expenditures -4.77M -17.86M -169.85M -76.6M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 82.76M 103.17M 164.36M 431.99M
Income Before Tax -83.13M -20.22M 401.64M 462.83M
Net Income -38.38M 573.02M 389.8M 534.49M
Selling General Administrative 686.74M 696.11M 973.23M 1.41B
Gross Profit 833.58M 937.94M 1.67B 2.46B
Ebit 64.08M 138.66M 530.14M 614.23M
Operating Income 64.08M 138.66M 530.14M 614.23M
Interest Expense -121.69M -87.09M -59.62M -81.06M
Income Tax Expense -44.75M -593.24M 11.85M -71.66M
Total Revenue 1.21B 1.3B 2.2B 3.23B
Cost Of Revenue 373.99M 362.09M 532.7M 766.94M
Total Other Income ExpenseNet -147.22M -158.89M -128.5M -151.41M
Net Income From Continuing Ops -38.38M 573.02M 389.8M 534.49M
Net Income Applicable To Common Shares -38.38M 573.02M 389.8M 534.49M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.75B 2.25B 2.05B 4.01B
Total Stockholder Equity 1.19B 2.19B 4.03B 4.67B
Other Current Liabilities 53.03M 54.91M 56.96M 71.67M
Total Assets 3.94B 4.44B 6.07B 8.68B
Common Stock 17k 19k 22k 23k
Other Current Assets 39.24M 75.43M 74.4M 132.92M
Retained Earnings -1.18B -605.68M -215.89M 318.61M
Treasury Stock -6.11M -6.49M -4.73M -19.57M
Cash 958.71M 1.08B 2.08B 1.58B
Total Current Liabilities 708.69M 723.17M 875.74M 886.57M
Other Stockholder Equity -1.52M -1.91M -145k -14.99M
Property, Plant, and Equipment 20.1M 69.96M 223.44M 368M
Total Current Assets 1.55B 1.69B 3.07B 2.8B
Net Tangible Assets -1.17B 69.15M 1.83B -234.43M
Net Receivables 464.73M 408.69M 659.7M 632.77M
Accounts Payable 30.28M 21.51M 37.71M 30.12M


Insider Transactions

Here are the insider transactions of stock shares related to Horizon Therapeutics Plc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
PASTERNAK ANDREWD2022-11-01Officer12.42k
CLAYTON SEAN M.Purchase at price 66.67 per share.I2022-08-04General Counsel745
PASTERNAK ANDREWSale at price 82.44 - 83.45 per share.D2022-07-29Officer4.85k
THOMPSON ELIZABETH H.Z.Sale at price 85.00 - 85.04 per share.D2022-07-20Officer6.01k
THOMPSON ELIZABETH H.Z.Sale at price 85.01 per share.D2022-07-07Officer82
PASTERNAK ANDREWSale at price 85.36 per share.D2022-06-10Officer762
WALBERT TIMOTHY PSale at price 92.08 - 92.74 per share.D2022-06-03Chief Executive Officer25k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-06-03Chief Executive Officer25k
WALBERT TIMOTHY PSale at price 92.04 - 94.46 per share.D2022-05-31Chief Executive Officer25k
WALBERT TIMOTHY PSale at price 90.00 per share.D2022-05-20Chief Executive Officer25k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-05-20Chief Executive Officer25k
WALBERT TIMOTHY PSale at price 90.00 per share.D2022-05-11Chief Executive Officer17.6k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-05-11Chief Executive Officer17.6k
WALBERT TIMOTHY PSale at price 90.33 - 91.11 per share.D2022-05-06Chief Executive Officer7.4k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-05-06Chief Executive Officer7.4k
WALBERT TIMOTHY PSale at price 95.38 - 97.43 per share.D2022-05-02Chief Executive Officer25k
WATKINS THOMASI2022-04-29Director4.22k
GREY MICHAEL G.I2022-04-29Director4.22k
DANIEL WILLIAM FI2022-04-29Director4.22k
SANTINI GINOI2022-04-29Director4.22k
WATKINS H. THOMASI2022-04-29Director4.22k
HIMAWAN JEFFI2022-04-29Director4.22k
MAHONY SUSAN MI2022-04-29Director4.22k
SHANNON JAMES SAMUELI2022-04-29Director4.22k
WITZ PASCALEI2022-04-29Director4.22k
WALBERT TIMOTHY PSale at price 106.10 - 109.39 per share.D2022-04-22Chief Executive Officer25k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-04-22Chief Executive Officer25k
HOELSCHER PAUL WSale at price 114.36 - 115.17 per share.D2022-04-20Chief Financial Officer50k
HOELSCHER PAUL WConversion of Exercise of derivative security at price 22.14 per share.D2022-04-20Chief Financial Officer50k
THOMPSON ELIZABETH H.Z.Sale at price 115.64 per share.D2022-04-18Officer8.1k
DESJARDIN MICHAEL ASale at price 112.55 - 113.60 per share.D2022-04-12Officer20.21k
WALBERT TIMOTHY PSale at price 111.70 - 112.72 per share.D2022-04-08Chief Executive Officer25k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-04-08Chief Executive Officer25k
SHERMAN JEFFREY WSale at price 110.02 per share.D2022-04-06Officer42.01k
HOELSCHER PAUL WSale at price 110.01 per share.D/I2022-04-06Chief Financial Officer307.05k
HOELSCHER PAUL WConversion of Exercise of derivative security at price 15.96 - 22.14 per share.D2022-04-06Chief Financial Officer215.34k
WALBERT TIMOTHY PSale at price 104.61 - 105.52 per share.D2022-03-30Chief Executive Officer50k
WALBERT TIMOTHY PSale at price 109.37 per share.D2022-03-25Chief Executive Officer25k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-03-25Chief Executive Officer25k
HOELSCHER PAUL WSale at price 110.00 - 110.01 per share.D/I2022-03-25Chief Financial Officer39.93k
HOELSCHER PAUL WConversion of Exercise of derivative security at price 15.96 per share.D2022-03-23Chief Financial Officer26.09k
SHERMAN JEFFREY WConversion of Exercise of derivative security at price 22.14 per share.D2022-03-18Officer8.53k
WALBERT TIMOTHY PSale at price 100.77 - 101.38 per share.D2022-03-11Chief Executive Officer25k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-03-11Chief Executive Officer25k
SHERMAN JEFFREY WStock Gift at price 0.00 per share.D/I2022-03-10Officer25.76k
HOELSCHER PAUL WStock Gift at price 0.00 per share.D/I2022-03-07Chief Financial Officer238.85k
DESJARDIN MICHAEL ASale at price 97.05 - 97.42 per share.D2022-03-02Officer35k
WALBERT TIMOTHY PSale at price 90.41 - 93.57 per share.D2022-02-28Chief Executive Officer75k
WALBERT TIMOTHY PConversion of Exercise of derivative security at price 22.14 per share.D2022-02-25Chief Executive Officer25k
PASTERNAK ANDREWSale at price 94.82 per share.D2022-02-18Officer1.31k
WALBERT TIMOTHY PSale at price 97.32 - 97.74 per share.D2022-02-11Chief Executive Officer25k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Horizon Therapeutics Plc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Horizon Therapeutics Plc

Here is the result of two systematic investment strategies applied to Horizon Therapeutics Plc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Horizon Therapeutics Plc

The following chart shows the equity curve of the two systematic investment strategies applied to Horizon Therapeutics Plc:

Horizon Therapeutics Plc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 252.64% on the backtest period.

Performance at glance

Performance

252.64 %

Latent gain

4440.05 $

Invested capital

1757.47 $

Annualized return

61.62 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Horizon Therapeutics Plc

This is the result of two momentum investment strategies applied to Horizon Therapeutics Plc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Horizon Therapeutics Plc

The following chart shows all the entries opened by the momentum investment system on Horizon Therapeutics Plc:

Horizon Therapeutics Plc momentum entries
  • The first momentum investment strategy would give 291.36% of return on Horizon Therapeutics Plc. That represents 15407.22$ of latent gain with 5288.07$ of employed capital.
  • The second momentum investment strategy would give 283.57% of return on Horizon Therapeutics Plc. That represents 7199.94$ of latent gain with 2539.02$ of employed capital.
Performance at glance (1Q Momentum)

Performance

291.36 %

Latent gain

15407.22 $

Invested capital

5288.07 $

Annualized return

105.18 %
Performance at glance (2Q Momentum)

Performance

283.57 %

Latent gain

7199.94 $

Invested capital

2539.02 $

Annualized return

78.33 %

Momentum equity curve on Horizon Therapeutics Plc

The following chart shows the equity curve of the two momentum strategies applied to Horizon Therapeutics Plc:

Horizon Therapeutics Plc momentum equity

Note: the dividends potentially given by Horizon Therapeutics Plc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Horizon Therapeutics Plc

The following chart shows the employed capital evolution of the two momentum strategies on Horizon Therapeutics Plc since the beginning:

Horizon Therapeutics Plc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Horizon Therapeutics Plc

Buy the dip entry openings on Horizon Therapeutics Plc

Horizon Therapeutics Plc

The performance achieved by the robo-advisor on Horizon Therapeutics Plc is 220.88%. That represents 533.26$ of latent gain with 241.43$ of employed capital. The following chart shows Horizon Therapeutics Plc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Horizon Therapeutics Plc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

220.88 %

Latent gain

533.26 $

Invested capital

241.43 $

Annualized return

105.18 %

Equity curve of the strategy applied to Horizon Therapeutics Plc

The following chart shows the result of the investment strategy applied to Horizon Therapeutics Plc:

Horizon Therapeutics Plc

Note: the dividends potentially given by Horizon Therapeutics Plc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Horizon Therapeutics Plc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Horizon Therapeutics Plc:

Horizon Therapeutics Plc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Horizon Therapeutics Plc

In this section, I will compare the three previous investment strategies applied to Horizon Therapeutics Plc.

Equity curve comparison on Horizon Therapeutics Plc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Horizon Therapeutics Plc investment strategy comparison

Employed capital comparison on Horizon Therapeutics Plc

Horizon Therapeutics Plc investment comparison

Performance comparison on Horizon Therapeutics Plc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 252.64% 4440.05$ 1757.47$ 61.62%
Momentum 1 quarter 291.36% 15407.22$ 5288.07$ 75.48%
Momentum 2 quarters 283.57% 7199.94$ 2539.02$ 78.33%
Non-directional 220.88% 533.26$ 241.43$ 105.18%
Annualized return comparison

Automatic investment

61.62 %

Momentum 1Q

78.33 %

Momentum 2Q

78.33 %

Non-directional

105.18 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Horizon Therapeutics Plc:

Positive correlations

Most correlated stocks this year

  • Horizon Therapeutics Plc

  • Most correlated stocks last 3 months

  • Carrols Restaurant Group Inc
  • Boston Beer Co. Inc - Class A
  • Horizon Therapeutics Plc
  • Blackrock Inc
  • SCOTTISH MORTGAGE INVESTMENT TRUST PLC ORD 5P
  • Papa John`s International Inc
  • Radcom
  • Solaredge Technologies Inc
  • FRANKLIN FTSE TAIWAN ETF
  • Invesco Variable Rate Investment Grade ETF
  • American Century Quality Diversified International
  • Sherwin-Williams Company
  • Amplify Transformational Data Sharing ETF
  • Applied Materials Inc
  • IQ Hedge Market Neutral Tracker ETF
  • Carvana Co. - Class A
  • Principal Millennial GlobalGrowth ETF
  • IQ Hedge Multi-Strategy Tracker ETF
  • Lazydays Holdings Inc
  • CarParts.com Inc
  • IVANHOE MINES LTD
  • BeiGene Ltd
  • McCormick & Co. Inc (Non Voting)
  • WisdomTree PutWrite Strategy Fund
  • S&P Emerging Markets Small Cap ETF
  • iShares MSCI Taiwan ETF
  • SPDR S&P Emerging Asia Pacific ETF
  • First Trust Chindia ETF
  • RH - Class A
  • IFAST
  • ARK Innovation ETF
  • Zillow Group Inc - Class C
  • Zillow Group Inc - Class A
  • AI Powered Equity ETF
  • Lowe`s Cos. Inc
  • Gadsden Dynamic Multi-Asset ETF
  • Biolife Solutions Inc
  • Invesco DWA Consumer Cyclicals Momentum ETF
  • Schwab U.S. Large-Cap Growth ETF
  • First Trust Dorsey Wright Dynamic Focus 5 ETF
  • Fidelity Nasdaq Composite Index ETF
  • First Trust Large Capital Growth AlphaDEX Fund
  • First Trust US Equity Opportunities ETF
  • Vanguard Russell 1000 Growth Index ETF
  • First Trust Technology AlphaDEX Fund
  • First Trust SSI Strategic Convertible Securities E
  • SPDR Bloomberg Convertible Securities ETF
  • UBS AG London Branch
  • ADVISORSHARES DORSEY WRIGHT ADR ETF
  • Idexx Laboratories Inc
  • Nidec Corporation
  • SPDR S&P Kensho Smart Mobility ETF
  • Amplify Online Retail ETF
  • Williams-Sonoma Inc
  • Cadence Design Systems Inc
  • FlexShares Quality Dividend Index Fund
  • FlexShares Quality Dividend Dynamic Index Fund
  • SPDR MSCI Emerging Markets StrategicFactors SM ETF
  • Fidelity MSCI Information Technology Index ETF

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • BAOFENGMODERN

  • Note: The algorithm computes the probability of correlation between Horizon Therapeutics Plc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Horizon Therapeutics Plc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Horizon Therapeutics Plc
    Country Ireland
    City Dublin
    Address 70 St. Stephen’s Green
    Phone 353 1 772 2100
    Website www.horizontherapeutics.com
    FullTime employees 2095
    Industry Drug Manufacturers—General
    Sector Healthcare
    Exchange XNAS
    Ticker HZNP
    Market www.nasdaq.com

    Horizon Therapeutics Plc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown